Get the Stockscreener App
3.82
5.21%
-0.21
Pre-market:
3.89
0.07
+1.83%
Iovance Biotherapeutics Inc stock is traded at $3.82, with a volume of 9.00M.
It is down -5.21% in the last 24 hours and up +10.72% over the past month.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
See More
Previous Close:
$4.03
Open:
$4.07
24h Volume:
9.00M
Relative Volume:
0.62
Market Cap:
$1.71B
Revenue:
$285.55M
Net Income/Loss:
$-353.86M
P/E Ratio:
-4.0206
EPS:
-0.9501
Net Cash Flow:
$-305.02M
1W Performance:
-1.55%
1M Performance:
+10.72%
6M Performance:
+69.78%
1Y Performance:
+83.65%
1-Day Range:
$3.80
$4.125
1-Week Range:
$3.70
$4.23
52-Week Range:
$1.66
$5.63
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Name
Iovance Biotherapeutics Inc
Sector
Industry
Phone
(650) 260-7120
Address
825 INDUSTRIAL ROAD, SAN CARLOS
Compare IOVA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
3.82 | 1.80B | 285.55M | -353.86M | -305.02M | -0.9501 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Upgrade | Citizens | Mkt Perform → Mkt Outperform |
| Jul-15-25 | Downgrade | Goldman | Neutral → Sell |
| May-16-25 | Downgrade | UBS | Buy → Neutral |
| May-12-25 | Downgrade | Truist | Buy → Hold |
| May-09-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Oct-24-24 | Initiated | UBS | Buy |
| Jul-29-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-20-23 | Initiated | Goldman | Buy |
| Sep-18-23 | Reiterated | Barclays | Overweight |
| May-30-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-27-23 | Resumed | Wells Fargo | Equal Weight |
| Jan-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-09-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-31-22 | Initiated | Guggenheim | Neutral |
| Aug-18-22 | Resumed | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Stifel | Hold → Buy |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Jun-10-21 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| May-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-21 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| May-19-21 | Downgrade | Stifel | Buy → Hold |
| May-03-21 | Initiated | Truist | Buy |
| Apr-16-21 | Initiated | Goldman | Buy |
| Mar-08-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-15-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-06-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-22-20 | Initiated | Mizuho | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-26-20 | Reiterated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | JMP Securities | Mkt Outperform |
| Oct-01-19 | Initiated | Stifel | Buy |
| Apr-29-19 | Initiated | Piper Jaffray | Overweight |
| Feb-28-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-07-19 | Initiated | Robert W. Baird | Outperform |
| Dec-31-18 | Resumed | B. Riley FBR | Buy |
| Jul-06-18 | Reiterated | Chardan Capital Markets | Buy |
| Apr-10-18 | Upgrade | B. Riley FBR, Inc. | Neutral → Buy |
| Mar-13-18 | Reiterated | B. Riley FBR, Inc. | Neutral |
| Feb-23-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Jan-25-18 | Reiterated | H.C. Wainwright | Buy |
| Nov-01-17 | Reiterated | B. Riley FBR, Inc. | Buy |
View All
Iovance Biotherapeutics Inc Stock (IOVA) Latest News
5 Best Penny Stocks That Could Skyrocket in 2026 - Insider Monkey
IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? - Stocktwits
Amtagvi Approval Boosted Iovance Biotherapeutics, Inc. (IOVA), But Can the Rally Last? - Yahoo Finance
After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why - Stocktwits
IOVANCE BIOTHERAPEUTICS INC (IOVA) Stock Chart - ChartMill
symbol__ Stock Quote Price and Forecast - CNN
Iovance Biotherapeutics (IOVA) reports Q1 loss, lags revenue estimates - MSN
Iovance Biotherapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Iovance Shareholders Approve Expanded Capital Flexibility and Governance - TipRanks
Iovance (NASDAQ: IOVA) gains Australian Amtagvi approval as shareholders back larger share pool - Stock Titan
Iovance Biotherapeutics (IOVA) Advances Next-Generation TIL Pipeline With FDA Clearance for IOV-5001 - Insider Monkey
IOVA: All proposals passed; strong growth, robust pipeline, and focus on revenue and margin improvement - TradingView
Iovance Biotherapeutics: Progress With Caveats (NASDAQ:IOVA) - Seeking Alpha
Iovance Biotherapeutics (IOVA) 10K Form and Latest SEC Filings 2026 - MarketBeat
Iovance rises as Australia approves melanoma therapy Amtagvi - MSN
IOVANCE (NASDAQ: IOVA) interim CEO reports RSU vesting and tax-share withholding - Stock Titan
IOVANCE (IOVA) Chief Medical Officer logs RSU vesting, tax-withheld shares in Form 4 - Stock Titan
Iovance (NASDAQ: IOVA) CRO reports RSU vesting and tax share withholding - Stock Titan
IOVANCE (NASDAQ: IOVA) COO RSUs vest; 3,976 shares withheld for tax - Stock Titan
IOVA Stock Slump Takes Wall Street, Retail By Surprise — Here’s Why - Stocktwits
Iovance’s Amtagvi® (lifileucel) receives approval for treatment of Advanced Melanoma in Australia - BioSpectrum Asia
Iovance Biotherapeutics, Inc. (IOVA) a Top Penny Stock to Buy on Amtagvi Strong Adoption - Yahoo Finance
Iovance Biotherapeutics (IOVA) Sees Revenue Surge 45% on Amtagvi Growth Despite Analyst Price Target AdjustmentEarnings Call Highlights - newsline.com
A Look At Iovance Biotherapeutics (IOVA) Valuation After Australian Conditional Approval For Amtagvi - Yahoo Finance
Iovance Biotherapeutics (IOVA) Slides 3.4% as Biotech Sector Faces Renewed PressureSmart Money Flow Stocks - newsline.com
Iovance Biotherapeutics (IOVA) Up 11% Since Q1 2026, Does it Have Further Upside Potential? - Insider Monkey
Is Iovance Biotherapeutics, Inc. (IOVA) One of the Most Shorted Small-Cap Stocks to Buy Now? - Insider Monkey
REPL Vs IOVA: FDA Decision Day Could Test Biotech Bulls’ Conviction On These Melanoma Plays - Stocktwits
Why Did IOVA Stock Gain Pre-Market Today? - Stocktwits
Australia approves Iovance’s Amtagvi for advanced melanoma By Investing.com - Investing.com Nigeria
IOVA News | IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) - ChartMill
5 Stocks Crushing the Market With Surging Returns - Insider Monkey
Iovance Biotherapeutics (IOVA) Gets Australia Nod for Amtagvi, Climbs 15% - Insider Monkey
IOVA: AMTAGVI’s rapid growth and strong clinical data drive expansion, with pivotal trials and new therapies advancing - TradingView
Iovance Biotherapeutics (IOVA) Secures Conditional Approval for Amtagvi in Australia - GuruFocus
Iovance wins Australian nod for melanoma drug (IOVA:NASDAQ) - Seeking Alpha
Australia approves Iovance’s Amtagvi for advanced melanoma - Investing.com Australia
Iovance’s Amtagvi granted Australian approval - The Pharma Letter
Iovance Biotherapeutics (IOVA) Receives Conditional Approval for Amtagvi in Australia - GuruFocus
Iovance stock gains after Australia approves melanoma therapy - Investing.com
Iovance stock gains after Australia approves melanoma therapy By Investing.com - Investing.com India
Iovance Biotherapeutics Inc Stock (IOVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Iovance Biotherapeutics Inc Stock (IOVA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Jun 05 '26 |
Option Exercise |
0.00 |
7,813 |
0 |
144,087 |
| Puri Raj K. | Chief Regulatory Officer |
Jun 05 '26 |
Option Exercise |
0.00 |
9,766 |
0 |
251,957 |
| BILINSKY IGOR | Chief Operating Officer |
Jun 05 '26 |
Option Exercise |
0.00 |
7,813 |
0 |
137,896 |
| Vogt Frederick G | Interim CEO & General Counsel |
Jun 01 '26 |
Option Exercise |
0.00 |
41,668 |
0 |
571,206 |
| Puri Raj K. | Chief Regulatory Officer |
Jun 01 '26 |
Option Exercise |
0.00 |
5,469 |
0 |
244,699 |
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Jun 01 '26 |
Option Exercise |
0.00 |
8,790 |
0 |
140,747 |
| BILINSKY IGOR | Chief Operating Officer |
Jun 01 '26 |
Option Exercise |
0.00 |
8,790 |
0 |
134,556 |
| Kirby Daniel Gordon | Chief Commercial Officer |
May 11 '26 |
Option Exercise |
0.00 |
10,000 |
0 |
149,381 |
| Vogt Frederick G | Interim CEO & General Counsel |
Mar 05 '26 |
Option Exercise |
0.00 |
62,493 |
0 |
556,293 |
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Mar 05 '26 |
Option Exercise |
0.00 |
31,246 |
0 |
148,477 |
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):